Table 1.

Summary of available pneumococcal vaccines.

Vaccine [Ref]	Brand Name	Serotype Coverage	Recommended Age Groups	Dosing Schedules
PCV13 [31]	Prevnar 13 (Pfizer, Inc., New York, NY, US)	1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F	All infants and children 2–59 months of age Children * and adults ** ≥ 60 months of age with underlying medical conditions Adults ≥ 65 years of age	Infants ≥ 6 weeks and children ≤ 15 months: IM 0.5 mL per dose given at 2, 4, 6, and 12 through 15 months of age (for a total of 4 doses) Adults IM 0.5 mL as a single dose
PCV15 [10,32]	Vaxneuvance (Merck and Co, Inc., Rahway, NJ, US)	22F and 33F, in addition to PCV13 serotypes	All infants and children 2–59 months of age Children * and adults ** ≥60 months of age with underlying medical conditions Adults ≥65 years of age	Infants ≥6 weeks and children ≤15 months: IM 0.5 mL per dose given at 2, 4, 6, and 12 through 15 months of age (for a total of 4 doses) Adults IM 0.5 mL as a single dose
PCV20 [10]	Prevnar 20 (Pfizer, Inc., New York, NY, US)	8, 10A, 11A, 12F, 15B, 22F, and 33F, in addition to PCV13 serotypes	Adults 19–64 years of age with underlying medical conditions ** Adults ≥ 65 years of age	Adults IM 0.5 mL as a single dose If PCV20 is given, then PPSV23 is not required
PPSV23 [31]	Pneumovax 23 (Merck and Co, Inc., Rahway, NJ, US)	2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, 33F, in addition to PCV13 serotypes, less 6A	Children * and adults ** ≥ 60 months of age with underlying medical conditions Adults ≥65 years of age	IM or SC 0.5 mL as a single dose Administer PPSV23 ≥ 1 year after PCV13 or PCV15 Administer a final dose of PPSV23 ≥ 5 years after the previous dose of PPSV23 once the patient turns 65 years of age

* Immunocompetent children with chronic heart disease (particularly cyanotic congenital heart disease and heart failure), chronic lung disease (including asthma if treated with high dose corticosteroids), diabetes, cerebrospinal fluid leaks, or cochlear implants; children with functional or anatomic asplenia, including sickle cell disease or other hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction; children with immunocompromising conditions including congenital immunodeficiency (includes B- or T-cell deficiency, complement deficiencies and phagocytic disorders), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancies, solid organ transplant, or other diseases requiring immunosuppressive drugs (including long-term systemic corticosteroids and radiation therapy). ** Alcoholism, chronic heart disease (including heart failure, cardiomyopathies), chronic liver disease, chronic lung disease (including chronic obstructive pulmonary disease, emphysema, asthma), cigarette smoking, diabetes mellitus, cochlear implant, cerebrospinal fluid leaks, asplenia (congenital or acquired), sickle cell disease or other hemoglobinopathies, immunocompromising conditions (e.g., chronic renal failure, congenital or acquired immunodeficiency [including B- or T-cell deficiency, complement deficiencies and phagocytic disorders;], malignancy, HIV infection, Hodgkin disease, iatrogenic immunosuppression [including long-term systemic corticosteroid treatment, radiation therapy], leukemia, lymphoma, multiple myeloma, nephrotic syndrome, solid organ transplant). IM: Intramuscular; SC: Subcutaneous.